Arseneault, L, Cannon, M, Murray, R, Poulton, R, Caspi, A, Moffitt, TE (2002). Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study. British Medical Journal 325, 1212–1213.
Battisti, RA, Roodenrys, S, Johnstone, SJ, Pesa, N, Hermens, DF, Solowij, N (2010 a). Chronic cannabis users show altered neurophysiological functioning on Stroop task conflict resolution. Psychopharmacology 212, 613–624.
Battisti, RA, Roodenrys, S, Johnstone, SJ, Respondek, C, Hermens, DF, Solowij, N (2010 b). Chronic use of cannabis and poor neural efficiency in verbal memory ability. Psychopharmacology 209, 319–330.
Bhattacharyya, S, Atakan, Z, Martín-Santos, R, Crippa, JA, Kambeitz, J, Prata, D, Williams, S, Brammer, M, Collier, DA, McGuire, PK (2012 a). Preliminary report of biological basis of sensitivity to the effects of cannabis on psychosis: AKT1 and DAT1 genotype modulates the effects of Δ-9-tetrahydrocannabinol on midbrain and striatal function. Molecular Psychiatry. Published online 31 January 2012. doi:10.3390/v3071210.
Bhattacharyya, S, Crippa, JA, Allen, P, Martín-Santos, R, Borgwardt, S, Fusar-Poli, P, Rubia, K, Kambeitz, J, O'Carroll, C, Seal, ML, Giampietro, V, Brammer, M, Zuardi, AW, Atakan, Z, McGuire, PK (2012 b). Induction of psychosis by Δ9-tetrahydrocannabinol reflects modulation of prefrontal and striatal function during attentional salience processing. Archives of General Psychiatry 69, 27–36.
Bhattacharyya, S, Fusar-Poli, P, Borgwardt, S, Martín-Santos, R, Nosarti, C, O'Carroll, C, Allen, P, Seal, ML, Fletcher, PC, Crippa, JA, Giampietro, V, Mechelli, A, Atakan, Z, McGuire, P (2009). Modulation of mediotemporal and ventrostriatal function in humans by Δ9-tetrahydrocannabinol: a neural basis for the effects of Cannabis sativa on learning and psychosis. Archives of General Psychiatry 66, 442–451.
Bhattacharyya, S, Morrison, PD, Fusar-Poli, P, Martín-Santos, R, Borgwardt, S, Winton-Brown, T, Nosarti, C, O'Carroll, CM, Seal, M, Allen, P, Mehta, MA, Stone, JM, Tunstall, N, Giampietro, V, Kapur, S, Murray, RM, Zuardi, AW, Crippa, JA, Atakan, Z, McGuire, P (2010). Opposite effects of Δ-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacology 35, 764–774.
Borgwardt, SJ, Allen, P, Bhattacharyya, S, Fusar-Poli, P, Crippa, JA, Seal, ML, Fraccaro, V, Atakan, Z, Martín-Santos, R, O'Carroll, C, Rubia, K, McGuire, PK (2008). Neural basis of Δ-9-tetrahydrocannabinol and cannabidiol: effects during response inhibition. Biological Psychiatry 64, 966–973.
Brammer, MJ, Bullmore, ET, Simmons, A, Williams, SCR, Grasby, PM, Howard, RJ, Woodruff, PWR, Rabe-Hesketh, S (1997). Generic brain activation mapping in fMRI: a non-parametric approach. Magnetic Resonance Imaging 15, 763–770.
Bullmore, ET, Suckling, J, Overmeyer, S, Rabe-Hesketh, S, Taylor, E, Brammer, MJ (1999). Global, voxel and cluster tests, by theory and permutation, for a difference between two groups of structural MR images of the brain. IEEE Transactions on Medical Imaging 18, 32–42.
Cascini, F, Aiello, C, Di Tanna, G (2011). Increasing delta-9-tetrahydrocannabinol (Δ-9-THC) content in herbal cannabis over time: systematic review and meta-analysis. Current Drug Abuse Reviews 5, 32–40.
Caspi, A, Moffitt, TE, Cannon, M, McClay, J, Murray, R, Harrington, H, Taylor, A, Arseneault, L, Williams, B, Braithwaite, A, Poulton, R, Craig, IW (2005). Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene × environment interaction. Biological Psychiatry 57, 1117–1127.
Chambers, CD, Garavan, , Bellgrove, MA (2009). Insights into the neural basis of response inhibition from cognitive and clinical neuroscience. Neuroscience and Biobehavioural Reviews 33, 631–646.
Chesher, GB, Bird, KD, Jackson, DM, Perrignon, A, Starmer, GA (1990). The effects of orally administered delta 9-tetrahydrocannabinol in man on mood and performance measures: a dose–response study. Pharmacology, Biochemistry and Behavior 35, 861–864.
Curran, HV, Brignell, C, Fletcher, S, Middleton, P, Henry, J (2002). Cognitive subjective dose–response effects of acute oral Δ9-tetrahydrocannabinol (THC) in infrequent cannabis users. Psychopharmacology 164, 61–70.
Degenhardt, L, Coffey, C, Carlin, JB, Swift, W, Moore, E, Patton, GC (2010). Outcomes of occasional cannabis use in adolescence: 10-year follow-up study in Victoria, Australia. British Journal of Psychiatry 196, 290–295.
D'Souza, DC, Perry, E, MacDougall, L, Ammerman, Y, Cooper, TB, Wu, YT, Braley, G, Gueorguieva, R, Krystal, JH (2004). The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacology 29, 1558–1572.
D'Souza, DC, Sewell, RA, Ranganathan, M (2009). Cannabis and psychosis/schizophrenia: human studies. European Archives of Clinical Neurosciences 259, 413–431.
Enticott, PG, Ogloff, JR, Bradshaw, JL (2008). Response inhibition and impulsivity in schizophrenia. Psychiatry Research 157, 251–254.
Fleck, DE, Kotwal, R, Eliassen, JC, Lamy, M, DelBello, MP, Adler, CM, Durling, M, Cerullo, MA, Strakowski, SM (2011). Preliminary evidence for increased frontosubcortical activation on a motor impulsivity task in mixed episode bipolar disorder. Journal of Affective Disorders 133, 333–339.
Fusar-Poli, P, Broome, MR, Matthiasson, P, Woolley, JB, Johns, LC, Tabraham, P, Bramon, E, Valmaggia, L, William, SC, McGuire, P (2010). Spatial working memory in individuals at high risk for psychosis: longitudinal fMRI study. Schizophrenia Research 123, 45–52.
Fusar-Poli, P, Crippa, JA, Bhattacharyya, S, Borgwardt, SJ, Allen, P, Martín-Santos, R, Seal, M, Surguladze, SA, O'Carroll, C, Atakan, Z, Zuardi, AW, McGuire, PK (2009). Distinct effects of Δ9-tetrahydrocannabinol and cannabidiol on neural activation during emotional processing. Archives of General Psychiatry 66, 95–105.
Fusar-Poli, P, Radua, J, McGuire, P, Borgwardt, S (2011). Neuroanatomical maps of psychosis onset: voxel-wise meta-analysis of antipsychotic-naïve VBM studies. Schizophrenia Bulletin. Published online 17 November 2011. doi:10.1093/schbul/sbr134.
Gray, KM, Hart, CL, Christie, DK, Upadhyaya, HP (2008). Tolerability and effects of oral Δ9-tetrahydrocannabinol in older adolescents with marijuana use disorders. Pharmacology, Biochemistry and Behavior 91, 67–70.
Green, B, Kavanagh, D, Young, R (2003). Being stoned: a review of self-reported cannabis effects. Drug and Alcohol Review 22, 453–460.
Grotenhermen, F (2003). Pharmacokinetics and pharmacodynamics of cannabinoids. Clinical Pharmacokinetics 42, 327–360.
Gruber, SA, Yurgelun-Todd, DA (2005). Neuroimaging of marijuana smokers during inhibitory processing: a pilot investigation. Brain Research. Cognitive Brain Research 23, 107–118.
Hayasaka, S, Nichols, TE (2003). Validating cluster size inference: random field and permutation methods. Neuroimage 20, 2343–2356.
Henquet, C, Krabbendam, L, Spauwen, J, Kaplan, C, Lieb, R, Wittchen, HU, van Os, J (2004). Prospective cohort study of cannabis use, predisposition for psychosis, and psychotic symptoms in young people. British Medical Journal 330, 11–14.
Hester, R, Nestor, L, Garavan, H (2009). Impaired error awareness and anterior cingulate cortex hypoactivity in chronic cannabis users. Neuropsychopharmacology 4, 2450–2458.
Honea, R, Crow, TJ, Passingham, D, Mackay, CE (2005). Regional deficits in brain volume in schizophrenia: a meta-analysis of voxel-based morphometry studies. American Journal of Psychiatry 162, 2233–2245.
Honey, GD, Corlett, PR, Absolam, AR, Lee, M, Pomarol-Clotet, E, Murray, GK, McKenna, PJ, Bullmore, ET, Menon, DK, Fletcher, PC (2008). Individual differences in psychotic effects of ketamine are predicted by brain function measure under placebo. Journal of Neuroscience 28, 6295–7303.
Huddy, VC, Aron, AR, Harrison, M, Barnes, TR, Robbins, TW, Joyce, EM (2009). Impaired conscious and preserved unconscious inhibitory processing in recent onset schizophrenia. Psychological Medicine 39, 907–916.
Hughes, ME, Fulham, WR, Johnston, PK, Michie, PT (2012). Stop-signal response inhibition in schizophrenia: behavioural, event-related potential and functional neuroimaging data. Biological Psychiatry 89, 220–231.
Jardri, R, Pouchet, A, Pins, D, Thomas, P (2011). Cortical activations during auditory verbal hallucinations in schizophrenia: a coordinate-based meta-analysis. American Journal of Psychiatry 168, 73–81.
Kay, SR, Fiszbein, A, Opler, LA (1987). The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophrenia Bulletin 13, 261–276.
Kiehl, KA, Smith, AM, Hare, RD, Liddle, PF (2000). An event-related potential investigation of response inhibition in schizophrenia and psychopathy. Biological Psychiatry 48, 210–221.
Lemberger, L, Axelrod, J, Kopin, IJ (1971). Metabolism disposition of Δ9-tetrahydrocannabinol in man. Pharmacological Review 23, 371–380.
Lorenzetti, V, Lubman, DI, Whittle, S, Solowij, N, Yucel, M (2010). Structural MRI findings in long-term cannabis users: what do we know? Substance Use and Misuse 45, 1787–1808.
Martín-Santos, R, Fagundo, AB, Crippa, JA, Atakan, Z, Bhattacharyya, S, Allen, P, Fusar-Poli, P, Borgwardt, S, Seal, M, Busatto, GF, McGuire, P (2010). Neuroimaging in cannabis use: a systematic review of the literature. Psychological Medicine 40, 383–398.
Marvel, CL, Turner, BM, O'Leary, DS, Johnson, HJ, Pierson, RK, Pnoto, LL, Andreasen, NC (2007). The neural correlates of implicit sequence learning in schizophrenia. Neuropsychology 21, 761–777.
McDonald, B, Highley, JR, Walker, MA, Herron, BM, Cooper, SJ, Esiri, MM, Crow, TJ (2000). Anomalous asymmetry of fusiform and parahippocampal gyrus gray matter in schizophrenia: a postmortem study. American Journal of Psychiatry 157, 40–47.
McGuire, PK, Jones, P, Harvey, I, Williams, M, McGuffin, P, Murray, RM (1995). Morbid risk of schizophrenia for relatives of patients with cannabis-associated psychosis. Schizophrenia Research 15, 277–281.
Mechelli, A, Fusar-Poli, P, Papagni, SA, Tognin, S, Kambeitz, J, Fu, C, Picchioni, M, Walshe, M, Toulopoulou, T, Bramon, E, Murray, R, McGuire, P (2012). Genetic vulnerability to psychosis and cortical function: epistatic effects between DAAO and G72. Current Pharmacological Design 18, 510–517.
Meijer, JH, Schmitz, N, Nieman, DH, Becker, HE, van Amelsvoort, TA, Dingemans, PM, Linszen, DH, de Haan, L (2011). Semantic fluency deficits and reduced grey matter before transition to psychosis: a voxelwise correlational analysis. Psychiatry Research 194, 1–6.
Moore, THM, Zammit, S, Lingford-Hughes, A, Barnes, TRE, Jones, PB, Burke, M, Lewis, G (2007). Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet 370, 319–328.
Morrison, PD, Zois, V, McKeown, DA, Lee, TD, Holt, DW, Powell, JF, Kapur, S, Murray, RM (2009). The acute effects of synthetic intravenous Δ9-tetrahydrocannabinol on psychosis, mood and cognitive functioning. Psychological Medicine 39, 1607–1616.
Ohlsson, A, Lindgren, JE, Wahlen, A, Agurell, S, Hollister, LE, Gillespie, HK (1980). Plasma delta-9 tetrahydrocannabinol concentrations clinical effects after oral intravenous administration smoking. Clinical Pharmacology and Therapeutics 28, 409–416.
Peters, BD, de Koning, P, Dingemans, P, Becker, H, Linszen, DH, de Haan, L (2009). Subjective effects of cannabis before the first psychotic episode. Australian and New Zealand Journal of Psychiatry 43, 1155–1162.
Rabe-Hesketh, S, Bullmore, ET, Brammer, MJ (1997). The analysis of functional magnetic resonance images. Statistical Methods in Medical Research 6, 215–237.
Ramaekers, JG, Kauert, G, Theunissen, EL, Toennes, SW, Moeller, MR (2009). Neurocognitive performance during acute THC intoxication in heavy and occasional cannabis users. Journal of Psychopharmacology 23, 266–277.
Roberts, GM, Garavan, H (2010). Evidence of increased activation underlying cognitive control in ecstasy and cannabis users. Neuroimage 15, 429–435.
Rubia, K, Russell, T, Bullmore, ET, Soni, W, Brammer, MJ, Simmons, A, Taylor, E, Andrew, C, Giampietro, V, Sharma, T (2001 a). An fMRI study of reduced left prefrontal activation in schizophrenia during normal inhibitory function. Schizophrenia Research 52, 47–55.
Rubia, K, Russell, T, Overmeyer, S, Brammer, MJ, Bullmore, ET, Sharma, T, Simmons, A, William, SC, Giampetro, V, Andrew, CM, Taylor, E (2001 b). Mapping motor inhibition: conjunctive brain activations across different versions of go/no-go and stop tasks. Neuroimage 13, 250–261.
Rubia, K, Smith, AB, Brammer, MJ, Taylor, E (2007). Temporal lobe dysfunction in medication-naïve boys with attention-deficit/hyperactivity disorder during attention allocation and its relation to response variability. Biological Psychiatry 62, 999–1006.
Simmonds, DJ, Pekar, JJ, Mostofsky, SH (2008). Meta-analysis of go/no-go tasks demonstrating that fMRI activation associated with response inhibition task is task-dependent. Neuropsychologia 46, 224–232.
Smieskova, R, Fusar-Poli, P, Allen, P, Bendfeldt, K, Stieglitz, RD, Drewe, J, Radue, EW, McGuire, PK, Riecher-Rössler, A, Borgwardt, SJ (2010). Neuroimaging predictors of transition to psychosis – a systematic review and meta-analysis. Neuroscience and Biobehavioral Reviews 34, 1207–1222.
Stirling, J, Barkus, EJ, Nabosi, L, Irshad, S, Roemer, G, Schreudergoidheijt, B, Lewis, S (2008). Cannabis-induced psychotic-like experiences are predicted by high schizotypy. Confirmation of preliminary results in a large cohort. Psychopathology 41, 371–378.
Stone, JM, Howes, OD, Egerton, A, Kambeitz, J, Allen, P, Lythgoe, DJ, O'Gorman, RL, McLean, MA, Barker, GJ, McGuire, P (2010). Altered relationship between hippocampal glutamate levels and striatal dopamine function in subjects at ultra high risk of psychosis. Biological Psychiatry 68, 599–602.
Tapert, SF, Schweinsburg, AD, Drummond, SPA, Paulus, MP, Brown, SA, Yang, TT, Frank, LR (2007). Functional MRI of inhibitory processing in abstinent adolescent marijuana users. Psychopharmacology 194, 173–183.
Thirion, B, Pinel, P, Tucholka, A, Roche, A, Ciuciu, P, Mangin, JF, Poline, JB (2007). Structural analysis of fMRI data revisited: improving the sensitivity and reliability of fMRI group studies. IEEE Transactions on Medical Imaging 26, 1256–1269.
Thomas, H (1996). A community survey of adverse effects of cannabis use. Drug and Alcohol Dependence 42, 201–207.
Turken, AU, Vuilleumier, P, Mathalon, DH, Swick, D, Ford, JM (2003). Are impairments of action monitoring and executive control true dissociative dysfunctions in patients with schizophrenia? American Journal of Psychiatry 160, 1881–1883.
van Winkel, R; Genetic Risk and Outcome of Psychosis (GROUP) Investigators (2011). Family-based analysis of genetic variation underlying psychosis-inducing effects of cannabis: sibling analysis and proband follow-up. Archives of General Psychiatry 68, 148–157.
Winton-Brown, TT, Allen, P, Bhattacharrya, S, Borgwardt, SJ, Fusar-Poli, P, Crippa, JA, Seal, M, Martín-Santos, R, Ffytche, D, Zuardi, AW, Atakan, Z, McGuire, PK (2011). Modulation of auditory and visual processing by delta-9-tetrahydrocannabinol and cannabidiol: an fMRI study. Neuropsychopharmacology 36, 1340–1348.
Witthaus, H, Kaufmann, C, Bohner, G, Ozgurdal, S, Gudlowski, Y, Gallinat, J, Ruhrmann, S, Brune, M, Heinz, A, Klingebiel, R, Juckel, G (2009). Gray matter abnormalities in subjects at ultra-high risk for schizophrenia and first-episode schizophrenic patients compared to healthy controls. Psychiatry Research 173, 163–169.
Wolf, DH, Gur, RC, Valdez, JN, Loughead, J, Elliott, MA, Gur, R, Ragland, JD (2007). Alterations of fronto-temporal connectivity during word encoding in schizophrenia. Psychiatry Research 154, 221–232.
Zammit, S, Allebeck, P, Andreasson, S, Lundberg, I, Lewis, G (2002). Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study. British Medical Journal 325, 1199–1201.